Wilson Therapeutics AB, which is developing products for rare diseases, has appointed Vincent Metzler to take charge of its commercial planning and launch strategy.
Dr Metzler previously was marketing director at Alexion Pharmaceuticals Inc’s Swiss office where he was involved in the successful launch of the company’s first product, Soliris, for a rare blood disease. He holds an MSc in chemistry and biology from the Louis Pasteur University in Strasbourg, France and a PhD in molecular biology from the University of Bern, Switzerland.
Wilson Therapeutics’ lead product is a treatment for Wilson’s disease, an inherited disorder that causes too much copper to accumulate in the liver or the brain.
Wilson Therapeutics announced the appointment on 15 August 2016.
Copyright 2016 Evernow Publishing Ltd